Postop Pain Management in Pituitary Tumour Patients
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18-100
SponsorHamilton Health Sciences Corporation
About this trial
To assess the benefit of using an additional nerve block during minimally invasive pituitary surgery, to improve pain management after surgery. The medication (Bupivacaine) or a placebo (saline) will be injected during surgery and patients will be asked about their level of pain at multiple time points in the first 24 hours following surgery. Some patients will be randomized to a third, sham group that do not receive any additional injection. The aim is to improve patient outcomes and reduce the need for pain medication after surgery.
Eligibility criteria
Qualifiers
adult patients (18 yrs or older)
undergoing endonasal pituitary adenoma resection
Disqualifiers
Patients with pre-existing chronic pain conditions requiring antidepressants (serotonin reuptake inhibitors), benzodiazepines, gabapentin, or opioid drugs
contraindications to the performance of SPGB such as known allergy to used medications
chronic alcohol abuse
uncontrolled systemic arterial hypertension
Trial design
Treatments tested in this trial
- Bupivacaine-Epinephrine 0.5%-1:200,000 Injectable Solution
- Placebo
- Sham Comparator
Treatment groups
108 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov